Effects of essential phospholipids (EPL) on experimental cobalt-induced cardiomyopathy.
D000818:Animals; D009202:Cardiomyopathies / Q000097:blood / Q000139:chemically induced* / Q000201:enzymology / Q000473:pathology; D003035:Cobalt; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography; D003576:Electron Transport Complex IV / Q000032:analysis; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006003:Glycogen / Q000032:analysis; D006801:Humans; D006884:Hydroxybutyrate Dehydrogenase / Q000097:blood; D008297:Male; D009206:Myocardium / Q000201:enzymology; D010743:Phospholipids / Q000627:therapeutic use*; D051381:Rats; D013385:Succinate Dehydrogenase / Q000032:analysis; D013997:Time Factors
D005230:Fatty Acids, Nonesterified; D010743:Phospholipids; D003035:Cobalt; D006003:Glycogen; D006884:Hydroxybutyrate Dehydrogenase; D013385:Succinate Dehydrogenase; D003576:Electron Transport Complex IV; D003402:Creatine Kinase